Diligence memo · auto-generated · as of July 2, 2026
Nymirum, Inc.
Nymirum, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Nymirum, Inc. operates in Biotechnology, based in ANN ARBOR.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Nymirum, Inc. has raised $550K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $550K on 2009-05-08.
Most recent recorded round closed around 2009-05-08.
Valuation (modeled)modeled
Provath models Nymirum, Inc. at approximately $30M (range $293K–$344M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.10× the median modeled value of Pre-Seed Biotechnology companies in 2007–2009 (62 peers) — value vs value, same stage and era. Within the normal band (110% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 17.1 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 12% of Biotechnology peers (4293 compared).
Modeled value ranks above 36% of those peers.
Closest niche peers: Cellay, Inc., Cellutions Inc, Atherotech, Inc., Bio-Tree Systems, Inc., Theocorp Holding Company, LLC.
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.